Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

The oncolytic virus therapy – also being developed by ... when given ahead of Nexavar for hepatocellular carcinoma (HCC), the most common form of liver cancer. Sillajen has told the KBR however ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...

We then review the use of HCC vaccines, adjuvant immunotherapy, and oncolytic virotherapy, and describe the goals of future research in the development of treatments for HCC.

Biotech company PsiVac is developing Ixovex-1, the first patented virus with a single base pair mutation able to replicate rapidly, opening potential new treatment options for solid tumors and beyond.

That is the potential of oncolytic virus therapy, according to Chinese scientists working on the genetically engineered “tumour meltdown” treatment. They say these low-cost, high-impact ...

Patients will receive a combination of immunotherapy drugs and a tumor-busting "oncolytic" virus injected directly into the tumors. Neuroendocrine tumors originate from cells found throughout the ...